Locations:
Search IconSearch
February 1, 2024/Cancer/Research

Possibilities of CRISPR Technology (Podcast)

Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The gene editing technology CRISPR offers potential for treating both hematologic cancer and solid tumors.

“The promise with the technology is now we can use our own immune system and use it as a targeted therapy against cancer,” says Faiz Anwer, MD, a hematologist at Cleveland Clinic who leads bone marrow transplant, stem cell transplant and CAR T-cell therapy for multiple myeloma indication.

In a recent episode of Cleveland Clinic’s Cancer Advances podcast, Dr. Anwer provides an overview on the current state of CRISPR technology, including:

  • How the gene-editing technology works
  • Clinical studies indicating successful use of CRISPR technology
  • When CRISPR may be a preferred treatment compared to cellular therapies and stem cell transplants
  • The potential for treating genetic disorders, such as blindness, cystic fibrosis and liver conditions
  • Barriers to further development of treatments, including off-target effects and germline mutations

Advertisement

Click the podcast player above to listen to the episode now, or read on for a short edited excerpt. Check out more Cancer Advances episodes at clevelandclinic.org/podcasts/cancer-advances or wherever you get your podcasts.

Excerpt from the podcast:

Podcast host Dale Shepard, MD, PhD: When we think about this technology, give us a little bit of a background on how it’s been utilized for treating cancer so far.

Anwer: So, this is very timely because we just initiated a phase 1 clinical trial with a pharmaceutical company. It’s a multi-institute study where we’re using a cancer-fighting T cell – and T cells are immune cells. Their main job is to fight against infections as well as cancers. And through this CRISPR technology, the allogeneic cells which came from a healthy donor were modified. Those T cells are now able to find and attack and kill cancer cells. And we are using it for the treatment of multiple myeloma.

In this particular case, this cell is modified in four different ways where they have removed a T-cell receptor and inserted a new receptor, which can find a cancer target called the BCMA protein. And on the other end, through this technology, they have modified the cell, so it does not attack the patient’s body – so it does not cause graft-versus-host disease.

And they have also modified the cell in a way that the patient’s host immune system does not attack and kill the donor cell. So, it is protected from the rejection of these cells. Through these edits, now these cells can stay in the body and potentially be very effective in eradicating cancer from the body.

Related Articles

Image showing Dr. Gupta
June 20, 2024/Cancer/Research
Trailblazing Urothelial Cancer Treatments (Podcast)

Platinum-eligible phase 3 trial of enfortumab vedotin and pembrolizumab yields ‘unprecedented data’

Lung cancer cells
June 5, 2024/Cancer/Research
Impact of Tumor Burden on Survival for Patients with EGFR-Mutant NSCLC Treated with Osimertinib

Extent of baseline burden impacts progression-free and overall survival

cancer cells
June 4, 2024/Cancer/Research
Researchers Identify Tumor Microbiome Differences in Early- vs. Average-Onset Pancreatic Adenocarcinoma

Further study warranted to better understand the clinical implications of these findings

car T-cells
June 3, 2024/Cancer/Research
CAR T-Cell Treatment Offers Hope for Richter Transformation

Real-world study shows high response rates that are durable with commercial lisocabtagene maraleucel

Blood clot
May 17, 2024/Cancer/Research
Managing the Risks of Venous Thromboembolisms in Patients with Cancer

Oral anticoagulants may be beneficial but need to be balanced against bleeding risks

Doctors working on MGUS screening study
March 18, 2024/Cancer/Research
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Physician with patient
March 6, 2024/Cancer/Research
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Doctor measuring patient's waist size
February 26, 2024/Cancer/Research
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Ad